focus trial semaglutide Cardiovascular outcomes of and tirzepatide for patients with type 2 diabetes in clinical practice Focus on Semaglutide 2.4 mg/week

Many patients also experience weight loss whilst taking Ozempic, although it is important to note that Ozempic is not licensed for weight management in the UK (a higher dose formulation called Wegovy is specifically licensed for obesity)

I never found it alarming, but I know others who had a much stronger reaction early on

The drugs ability to significantly lower blood glucose levels and promote weight loss, potentially reducing the risk of diabetes-related complications, underscores its value in the therapeutic landscape

[DOI] [PMC free article] [PubMed] [Google Scholar] 22.Mott J., Dolan J.K., Gilor C., Gilor S